During the 2020 annual ASCO meeting, the most recent advances in squamous cell carcinoma of the head and neck as well as nasopharyngeal carcinoma were discussed. First of all, weekly cisplatin proved to be non-inferior to three-weekly cisplatin in the postoperative setting. Next, several interesting studies in both locoregionally advanced and recurrent/metastatic squamous cell carcinoma of the head and neck will be addressed. Finally, axitinib was shown to increase the six-month progression-free survival rate in patients with recurrent or metastatic adenoid cystic carcinoma.
(BELG J MED ONCOL 2020;14(5):222-6)